Department of Pathology, Odense University Hospital, Winsløwparken 15, 3. Floor, 5000, Odense C, Denmark.
J Neurooncol. 2013 Aug;114(1):13-23. doi: 10.1007/s11060-013-1155-x. Epub 2013 May 23.
Recent research suggests that deregulation of microRNAs (miRNAs) is involved in initiation and progression of many cancers, including gliomas and that miRNAs hold great potential as future diagnostic and therapeutic tools in cancer. MiRNAs are a class of short non-coding RNA sequences (18-24 nucleotides), which base-pair to target messenger RNA (mRNA) and thereby cause translational repression or mRNA degradation based on the level of complementarity between strands. Profiling miRNAs in clinical glioblastoma samples has shown aberrant expression of numerous miRNAs when compared to normal brain tissues. Understanding these alterations is key to developing new biomarkers and intelligent treatment strategies. This review presents an overview of current knowledge about miRNA alterations in glioblastoma while focusing on the clinical future of miRNAs as biomarkers and discussing the strengths and weaknesses of various methods used in evaluating their expression.
最近的研究表明，microRNAs（miRNAs）的失调参与了许多癌症的发生和发展，包括神经胶质瘤，并且 miRNAs 作为癌症的未来诊断和治疗工具具有很大的潜力。miRNAs 是一类短的非编码 RNA 序列（18-24 个核苷酸），它们与靶信使 RNA（mRNA）碱基配对，从而根据链之间互补程度引起翻译抑制或 mRNA 降解。与正常脑组织相比，对临床神经胶质瘤样本中的 miRNAs 进行分析显示，许多 miRNAs 的表达异常。了解这些改变对于开发新的生物标志物和智能治疗策略至关重要。本综述概述了目前关于神经胶质瘤中 miRNA 改变的知识，同时重点介绍了 miRNAs 作为生物标志物的临床未来，并讨论了评估其表达的各种方法的优缺点。
